CRDLCardiol Therapeutics Inc - Ordinary Shares - Class A
$1.02
$0.01
(0.99%)
Closed $1.00
$0.02
(2.00%)
After Hours
Reported EarningsMay 11
Mkt Cap$115.27M
Vol365,814.00
Cardiol Therapeutics Reports Results of 2026 Annual General Meeting of Shareholders
Cardiol Therapeutics Reports Results of 2026 Annual General Meeting of Shareholders Cardiol Therapeutics Reports Results of 2026 Annual General Meeting of Shareholders PR Newswire TORONTO, June 25, 2026 TORONTO, June 25, 2026 /PRNewswire/ -Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL...
PR Newswire
Cardiol Therapeutics to Webcast Virtual Annual General Meeting of Shareholders on June 24th at 4:30 p.m. EDT
Cardiol Therapeutics to Webcast Virtual Annual General Meeting of Shareholders on June 24th at 4:30 p.m. EDT Cardiol Therapeutics to Webcast Virtual Annual General Meeting of Shareholders on June 24th at 4:30 p.m. EDT PR Newswire TORONTO, June 23, 2026 TORONTO, June 23, 2026 /PRNewswire/ - Cardiol...
PR Newswire
Cardiol Therapeutics to Participate in Fireside Chat at H.C. Wainwright 4th Annual BioConnect Investor Conference at the NASDAQ
Cardiol Therapeutics to Participate in Fireside Chat at H.C. Wainwright 4th Annual BioConnect Investor Conference at the NASDAQ Cardiol Therapeutics to Participate in Fireside Chat at H.C. Wainwright...
PR Newswire
Cardiol Therapeutics' Phase II MAvERIC Results Accepted for Publication in the Journal of the American Heart Association
Cardiol Therapeutics' Phase II MAvERIC Results Accepted for Publication in the Journal of the American Heart Association Cardiol Therapeutics' Phase II MAvERIC Results Accepted for Publication in the...
PR Newswire
Cardiol Therapeutics Expands U.S. MAVERIC Phase III Trial Network to Address Growing Interest in the Pivotal Program
Cardiol Therapeutics Expands U.S. MAVERIC Phase III Trial Network to Address Growing Interest in the Pivotal Program Cardiol Therapeutics Expands U.S. MAVERIC Phase III Trial Network to Address...
PR Newswire
Cardiol Therapeutics (TSE:CRDL) Sets New 1-Year High - Here's Why
Cardiol Therapeutics (TSE:CRDL) Reaches New 52-Week High - Should You Buy...
MarketBeat
Cardiol Therapeutics (TSE:CRDL) Trading Up 7.9% - Here's What Happened
Cardiol Therapeutics (TSE:CRDL) Stock Price Up 7.9% - Should You Buy...
MarketBeat
Cardiol Therapeutics CEO: Phase III MAVERIC Nears Full Enrollment as CardiolRx Shows Myocarditis Promise
Cardiol Therapeutics (NASDAQ:CRDL) is aiming to address inflammation-driven heart disease with therapies the company believes could improve outcomes in conditions that currently have limited or no...
MarketBeat
Research Analysts Set Expectations for CRDL Q3 Earnings
Cardiol Therapeutics Inc. (NASDAQ:CRDL - Free Report) - Equities researchers at Brookline Capital Markets reduced their Q3 2026 EPS estimates for shares of Cardiol Therapeutics in a research report...
MarketBeat
What is HC Wainwright's Forecast for CRDL Q1 Earnings?
Cardiol Therapeutics Inc. (NASDAQ:CRDL - Free Report) - Equities researchers at HC Wainwright issued their Q1 2026 earnings per share (EPS) estimates for shares of Cardiol Therapeutics in a research...
MarketBeat
<
1
2
...
>
Advertisement|Remove ads.
Latest CRDL News
ViewCardiol Therapeutics Reports Results of 2026 Annual General Meeting of Shareholders
PR Newswire
Cardiol Therapeutics to Webcast Virtual Annual General Meeting of Shareholders on June 24th at 4:30 p.m. EDT
PR Newswire
Cardiol Therapeutics to Participate in Fireside Chat at H.C. Wainwright 4th Annual BioConnect Investor Conference at the NASDAQ
PR Newswire
Advertisement|Remove ads.